Abstract
Breast cancer, the most common form of cancer among women in North America and almost all of Europe, is a significant health problem in terms of both morbidity and mortality. It is estimated that each year this disease is diagnosed in over one million people worldwide and is the cause of more than 400,000 deaths. Although chemotherapy forms part of a successful treatment regime in many cases, as few as 50% patients may benefit from this, as a result of intrinsic or acquired multiple drug resistance (MDR). Through the use of in vitro cell culture models, a number of mechanisms of MDR have been identified; many, if not all, of which may contribute to breast cancer resistance in the clinical setting. This phenomenon is complicated by the likely multi-factorial nature of clinical resistance combined with the fact that, although apparently studied extensively in breast cancer, reported analyses have been performed using a range of analytical techniques; many on small sub-groups of patients, with different clinicopathological characteristics and receiving a range of therapeutic approaches. Larger defined studies, using standardised genomic and proteomics profiling approaches followed by functional genomics studies, are necessary in order to definitively establish the degree of complexity contributing to drug resistance and to identify novel therapeutic approaches - possibly involving chemotherapy, drug resistance modulators, and novel targeted therapies - to combat this disease.
Keywords: Breast cancer, biomarkers, chemotherapy, multiple drug resistance, molecular profiling, targeted therapy
Current Cancer Drug Targets
Title: Biomarkers and Multiple Drug Resistance in Breast Cancer
Volume: 6 Issue: 5
Author(s): L. O'Driscoll and M. Clynes
Affiliation:
Keywords: Breast cancer, biomarkers, chemotherapy, multiple drug resistance, molecular profiling, targeted therapy
Abstract: Breast cancer, the most common form of cancer among women in North America and almost all of Europe, is a significant health problem in terms of both morbidity and mortality. It is estimated that each year this disease is diagnosed in over one million people worldwide and is the cause of more than 400,000 deaths. Although chemotherapy forms part of a successful treatment regime in many cases, as few as 50% patients may benefit from this, as a result of intrinsic or acquired multiple drug resistance (MDR). Through the use of in vitro cell culture models, a number of mechanisms of MDR have been identified; many, if not all, of which may contribute to breast cancer resistance in the clinical setting. This phenomenon is complicated by the likely multi-factorial nature of clinical resistance combined with the fact that, although apparently studied extensively in breast cancer, reported analyses have been performed using a range of analytical techniques; many on small sub-groups of patients, with different clinicopathological characteristics and receiving a range of therapeutic approaches. Larger defined studies, using standardised genomic and proteomics profiling approaches followed by functional genomics studies, are necessary in order to definitively establish the degree of complexity contributing to drug resistance and to identify novel therapeutic approaches - possibly involving chemotherapy, drug resistance modulators, and novel targeted therapies - to combat this disease.
Export Options
About this article
Cite this article as:
O'Driscoll L. and Clynes M., Biomarkers and Multiple Drug Resistance in Breast Cancer, Current Cancer Drug Targets 2006; 6 (5) . https://dx.doi.org/10.2174/156800906777723958
DOI https://dx.doi.org/10.2174/156800906777723958 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial from Guest Editor (DNA Methylation: A Target for Current and Future Therapies?)
Epigenetic Diagnosis & Therapy (Discontinued) Pharmacophore Models and Development of Spirocyclic Ligands for σ1 Receptors
Current Pharmaceutical Design Epigenetic Control of MicroRNA Expression and Aging
Current Genomics Identification of Novel IRAK-4 Inhibitors Through Pharmacophore Modeling, Atom-based 3D-QSAR, Docking Strategies and Molecular Dynamics Simulation
Letters in Drug Design & Discovery Antioxidant Supplements, Genetics and Chemotherapy Outcomes
Current Cancer Therapy Reviews Molecular Biotheranostic Approaches of Cancers Using LAT Kit Probes
Current Medical Imaging DNA Damage-inducing Compounds: Unraveling their Pleiotropic Effects Using High Throughput Sequencing
Current Medicinal Chemistry Pharmacological Tools to Activate Microglia and their Possible use to Study Neural Network Patho-physiology
Current Neuropharmacology Anti-Inflammatory/Analgesic
Current Bioactive Compounds The Design of Amphiphilic Polymeric Micelles of Curcumin for Cancer Management
Current Medicinal Chemistry Recent Insights into COVID-19 in Children and Clinical Recommendations
Current Pediatric Reviews Advances in the Molecular Detection of ABC Transporters Involved in Multidrug Resistance in Cancer
Current Pharmaceutical Biotechnology Phosphoregulation of Twist1 Provides a Mechanism of Cell Fate Control
Current Medicinal Chemistry Anti-Metastatics: An Overview of Drug Candidates in Current Pipelines
Current Pharmaceutical Design Targeting Steroid Hormone Receptor Pathways in the Treatment of Hormone Dependent Cancers
Current Pharmaceutical Biotechnology Determination of the Apoptotic Effect and Molecular Docking of Benzamide Derivative XT5 in K562 Cells
Anti-Cancer Agents in Medicinal Chemistry Amniotic Fluid Stem Cells: a Promising Therapeutic Resource for Cell-Based Regenerative Therapy
Current Pharmaceutical Design Flavonoids in the Treatment of Diabetes: Clinical Outcomes and Mechanism to Ameliorate Blood Glucose Levels
Current Diabetes Reviews Lack of Association between NOD2 rs3135500 and IL12B rs1368439 microRNA Binding Site SNPs and Colorectal Cancer Susceptibility in an Iranian Population
MicroRNA Peptides Targeting Angiogenesis Related Growth Factor Receptors
Current Pharmaceutical Design